PRAME Kit ELISA

N° du produit ABIN5657995

Détail du produit PRAME Kit ELISA

Antigène: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Gamme de detection: 0.312 ng/mL - 20 ng/mL

Seuil minimal de détection: 0.312 ng/mL

Application: ELISA

Type d'échantillon: Cell Lysate, Tissue Homogenate

Analytical Method: Quantitative

Specificité: This assay has high sensitivity and excellent specificity for detection of Preferentially Expressed Antigen In Melanoma (PRAME). No significant cross-reactivity or interference between Preferentially Expressed Antigen In Melanoma (PRAME) and analogues was observed.

Sensibilité: 0.117 ng/mL

Information d'application

Commentaires:

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5 % within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Durée du test: 3 h

Plaque: Pre-coated

Protocole: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Preferentially Expressed Antigen In Melanoma (PRAME), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Preferentially Expressed Antigen In Melanoma (PRAME) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Précision du teste: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested 20 times on one plate, respectively
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Restrictions: For Research Use only

Stockage

Conseil sur la manipulation: The Stop Solution is acidic. Do not allow to contact skin or eyes. Calibrators, controls and specimen samples should be assayed in duplicate. Once the procedure has been started, all steps should be completed without interruption.

Stock: 4 °C,-20 °C

Stockage commentaire: -20°C. Bring all reagents to room temperature before beginning test. The kit may be stored at 4°C for immediate use within two days upon arrival. Reseal any unused strips with desiccant pack. Minimize freeze/thaw cycles.

Date de péremption: 4-8 months

Détail du antigène

Antigène: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Autre désignation: Preferentially Expressed Antigen In Melanoma (PRAME Produits)

Synonymes: PRAME Kit ELISA, CT130 Kit ELISA, MAPE Kit ELISA, OIP-4 Kit ELISA, OIP4 Kit ELISA, 4930534P07Rik Kit ELISA, preferentially expressed antigen in melanoma Kit ELISA, PRAME Kit ELISA, Prame Kit ELISA

Sujet:

Gene Name: Preferentially Expressed Antigen In Melanoma

Gene Aliases: MAPE, OIP4, CT130, Cancer/Testis Antigen 130, Opa-interacting protein 4, Melanoma antigen preferentially expressed in tumors

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding